NASDAQ:STAA - STAAR Surgical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$40.97 -1.84 (-4.30 %)
(As of 11/15/2018 06:00 AM ET)
Previous Close$42.81
Today's Range$40.88 - $43.6950
52-Week Range$13.60 - $54.00
Volume382,010 shs
Average Volume388,523 shs
Market Capitalization$1.90 billion
P/E Ratio4,097.00
Dividend YieldN/A
Beta2.05
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers minimally invasive intraocular lenses (IOLs), including foldable IOLs for use in minimally invasive cataract surgical procedures; aspheric IOLs that produce a clearer image than traditional spherical lenses; and nanoFLEX IOL, a single piece collamer aspheric optic, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision centers, surgical centers, hospitals, government facilities, and distributors primarily under the STAAR, EVO Visian ICL, Evolution in Visual Freedom, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, and Afinity trademarks. The company sells products directly through its sales representatives in the United States, Japan, Spain, Germany, Canada, the United Kingdom, and Singapore, as well as through independent distributors in approximately 75 countries. STAAR Surgical Company was founded in 1982 and is headquartered in Monrovia, California.

Receive STAA News and Ratings via Email

Sign-up to receive the latest news and ratings for STAA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Ophthalmic goods
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:STAA
Previous Symbol
CUSIP85231230
Phone626-303-7902

Debt

Debt-to-Equity Ratio0.01
Current Ratio5.35
Quick Ratio4.76

Price-To-Earnings

Trailing P/E Ratio4,097.00
Forward P/E Ratio455.22
P/E GrowthN/A

Sales & Book Value

Annual Sales$90.61 million
Price / Sales19.95
Cash Flow$0.0870 per share
Price / Cash470.93
Book Value$2.92 per share
Price / Book14.03

Profitability

EPS (Most Recent Fiscal Year)$0.01
Net Income$-2,130,000.00
Net Margins3.17%
Return on Equity14.80%
Return on Assets10.15%

Miscellaneous

Employees353
Outstanding Shares44,130,000
Market Cap$1.90 billion
OptionableOptionable

STAAR Surgical (NASDAQ:STAA) Frequently Asked Questions

What is STAAR Surgical's stock symbol?

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

How were STAAR Surgical's earnings last quarter?

STAAR Surgical (NASDAQ:STAA) released its quarterly earnings data on Wednesday, October, 31st. The medical instruments supplier reported $0.03 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.03) by $0.06. The medical instruments supplier had revenue of $31.77 million for the quarter, compared to the consensus estimate of $30.10 million. STAAR Surgical had a net margin of 3.17% and a return on equity of 14.80%. During the same period in the previous year, the company earned $0.03 earnings per share. View STAAR Surgical's Earnings History.

When is STAAR Surgical's next earnings date?

STAAR Surgical is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for STAAR Surgical.

What price target have analysts set for STAA?

4 equities research analysts have issued 12 month target prices for STAAR Surgical's stock. Their predictions range from $21.00 to $55.00. On average, they anticipate STAAR Surgical's stock price to reach $43.3333 in the next twelve months. This suggests a possible upside of 5.8% from the stock's current price. View Analyst Price Targets for STAAR Surgical.

What is the consensus analysts' recommendation for STAAR Surgical?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for STAAR Surgical.

What are Wall Street analysts saying about STAAR Surgical stock?

Here are some recent quotes from research analysts about STAAR Surgical stock:
  • 1. According to Zacks Investment Research, "Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma. " (11/8/2018)
  • 2. Canaccord Genuity analysts commented, "We view the Warning Letter lift as a bullish catalyst for the stock and the company, with the enormous potential growth engine that is the US market now fully accessible to STAA. While the near term now looks even brighter, we think the firm’s longer-term potential, both with presbyopia (a ~1.5M-patient annual TAM by company estimates) and with full entry into the US market (the second-largest refractive market in the world) acting as major growth drivers – drivers we expect to support sustained, double- digit organic growth into the next decade and beyond. We reiterate our BUY rating and increase our price target to $32 (9.1x EV/sales on 2020E)." (6/20/2018)

Has STAAR Surgical been receiving favorable news coverage?

Media coverage about STAA stock has trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. STAAR Surgical earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned media headlines about the medical instruments supplier a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future.

Who are some of STAAR Surgical's key competitors?

Who are STAAR Surgical's key executives?

STAAR Surgical's management team includes the folowing people:
  • Ms. Caren L. Mason, CEO, Pres & Director (Age 64)
  • Ms. Deborah Andrews, Chief Financial Officer (Age 61)
  • Dr. Keith Holliday, Chief Technology Officer (Age 55)
  • Mr. Samuel J. Gesten, Chief Legal Officer & Corp. Sec. (Age 56)
  • Mr. Hans-Martin Blickensdoerfer, Sr. VP of Commercial Operations - Europe & China (Age 53)

Who are STAAR Surgical's major shareholders?

STAAR Surgical's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.95%), Baillie Gifford & Co. (3.51%), Renaissance Technologies LLC (2.05%), Fuller & Thaler Asset Management Inc. (0.89%), Deutsche Bank AG (0.84%) and Kornitzer Capital Management Inc. KS (0.61%). Company insiders that own STAAR Surgical stock include Caren L Mason, Deborah J Andrews, Hans-Martin Blickensdoerfer, Keith Holliday, Samuel J Gesten and William P Wall. View Institutional Ownership Trends for STAAR Surgical.

Which major investors are selling STAAR Surgical stock?

STAA stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Hsbc Holdings PLC, Grandeur Peak Global Advisors LLC, Artemis Investment Management LLP, Candriam Luxembourg S.C.A., Rice Hall James & Associates LLC, EAM Investors LLC and Strs Ohio. Company insiders that have sold STAAR Surgical company stock in the last year include Caren L Mason, Deborah J Andrews, Keith Holliday, Samuel J Gesten and William P Wall. View Insider Buying and Selling for STAAR Surgical.

Which major investors are buying STAAR Surgical stock?

STAA stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Renaissance Technologies LLC, Kornitzer Capital Management Inc. KS, BlackRock Inc., Deutsche Bank AG, Hodges Capital Management Inc., American Century Companies Inc. and University of Notre Dame DU Lac. View Insider Buying and Selling for STAAR Surgical.

How do I buy shares of STAAR Surgical?

Shares of STAA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is STAAR Surgical's stock price today?

One share of STAA stock can currently be purchased for approximately $40.97.

How big of a company is STAAR Surgical?

STAAR Surgical has a market capitalization of $1.90 billion and generates $90.61 million in revenue each year. The medical instruments supplier earns $-2,130,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. STAAR Surgical employs 353 workers across the globe.

What is STAAR Surgical's official website?

The official website for STAAR Surgical is http://www.staar.com.

How can I contact STAAR Surgical?

STAAR Surgical's mailing address is 1911 WALKER AVENUE, MONROVIA CA, 91016. The medical instruments supplier can be reached via phone at 626-303-7902 or via email at [email protected]


MarketBeat Community Rating for STAAR Surgical (NASDAQ STAA)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  238 (Vote Underperform)
Total Votes:  399
MarketBeat's community ratings are surveys of what our community members think about STAAR Surgical and other stocks. Vote "Outperform" if you believe STAA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STAA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel